NASDAQ · EVOK
Evoke Pharma, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$11.00
Up+$11.00 (+0.00%)
Updated Sep 16, 2026, 12:02 PM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 18.86M
- P/E ratio
- -5.19
- Dividend yield
- 0.00%
- 52-week range
- $1.94 – $11.00
- Volume
- 47.11K
- Avg. volume
- 94.97K
Price performance
EVOK price history
1M range · 0 trading sessions · Daily adjusted prices
EVOK does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest EVOK news
The latest Smart Investors Daily articles mentioning EVOK.
Stock researchCompany · Overview
EVOK research
Overview
Company profile and research snapshot.
Company profile
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $18.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 22, 2020 | HC Wainwright & Co. | Buy | — |
| Mar 5, 2019 | H.C. Wainwright | Neutral | — |
| Oct 6, 2017 | Seaport Global | Buy | — |
| Jan 30, 2017 | Laidlaw & Co. | Buy | — |
| Jan 5, 2017 | Rodman & Renshaw | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.
